» Articles » PMID: 21864812

Reference Limits for N-terminal-pro-B-type Natriuretic Peptide in Healthy Individuals (from the Framingham Heart Study)

Overview
Journal Am J Cardiol
Date 2011 Aug 26
PMID 21864812
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) is a commonly measured cardiovascular biomarker in ambulatory and hospital settings. Nonetheless, there are limited data regarding "normal" ranges for NT-pro-BNP in healthy subjects, despite the importance of such information for interpreting natriuretic peptide measurements. In this study, a healthy reference sample free of cardiovascular disease from the Framingham Heart Study Generation 3 cohort was examined; there were 2,285 subjects (mean age 38 years, 56% women). Plasma NT-pro-BNP levels were measured using the Roche Diagnostics Elecsys 2010 assay, and reference values (2.5th, 50th, and 97.5th quantiles) were determined using empiric and quantile regression methods. Gender, age, blood pressure, and body mass index accounted for approximately 33% of the interindividual variability in NT-pro-BNP in the reference sample. NT-pro-BNP values were substantially higher in women compared to men at every age, and levels increased with increasing age for both genders. Using quantile regression, the upper reference values (97.5th quantile) for NT-pro-BNP were 42.5 to 106.4 pg/ml in men (depending on age) and 111.0 to 215.9 pg/ml in women. Intraindividual variability was assessed in an additional 12 healthy subjects, who had serial NT-pro-BNP measurements over 1 month. Intraclass correlation was 0.85, indicating that most of the variability in NT-pro-BNP concentrations was among rather than within subjects. However, the reference change value was 100%, suggesting that small proportional differences in NT-pro-BNP could be attributable to analytic variability. In conclusion, the reference limits obtained from this large, healthy, community-based sample may aid in the evaluation of NT-pro-BNP concentrations measured for clinical and research purposes.

Citing Articles

Differences in natriuretic peptide response in self-identified white and black individuals: a physiological clinical trial.

Shetty N, Gaonkar M, Patel N, Vekariya N, Yerabolu K, Dhaliwal J Nat Commun. 2025; 16(1):1621.

PMID: 39948072 PMC: 11825667. DOI: 10.1038/s41467-024-55648-2.


Analytical and clinical performance evaluation of a new NT-proBNP assay.

Feng P, Qin J, Chai Z, Zhang Y, Zhao M, Liu L BMC Cardiovasc Disord. 2024; 24(1):341.

PMID: 38969996 PMC: 11229486. DOI: 10.1186/s12872-024-03994-w.


A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors.

Leerink J, Feijen E, de Baat E, Merkx R, van der Pal H, Tissing W JACC CardioOncol. 2024; 6(2):236-247.

PMID: 38774012 PMC: 11103045. DOI: 10.1016/j.jaccao.2024.02.008.


Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy.

Ehrhardt M, Liu Q, Mulrooney D, Rhea I, Dixon S, Lucas Jr J J Clin Oncol. 2024; 42(11):1265-1277.

PMID: 38207238 PMC: 11095874. DOI: 10.1200/JCO.23.01796.


Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort Analysis.

Patel K, Segar M, Klonoff D, Khan M, Usman M, Lam C Circulation. 2023; 149(4):293-304.

PMID: 37950893 PMC: 11257100. DOI: 10.1161/CIRCULATIONAHA.123.067530.


References
1.
Hess G, Runkel S, Zdunek D, Hitzler W . Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP): a study in blood donors. Clin Chim Acta. 2005; 360(1-2):187-93. DOI: 10.1016/j.cccn.2005.04.031. View

2.
Redfield M, Rodeheffer R, Jacobsen S, Mahoney D, Bailey K, Burnett Jr J . Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002; 40(5):976-82. DOI: 10.1016/s0735-1097(02)02059-4. View

3.
Wei Y, Pere A, Koenker R, He X . Quantile regression methods for reference growth charts. Stat Med. 2005; 25(8):1369-82. DOI: 10.1002/sim.2271. View

4.
Wu A . Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J. 2006; 152(5):828-34. DOI: 10.1016/j.ahj.2006.08.021. View

5.
Chang A, Abdullah S, Jain T, Stanek H, Das S, McGuire D . Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol. 2007; 49(1):109-16. DOI: 10.1016/j.jacc.2006.10.040. View